Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2909-2915

  Piazza, Gary A ^a   Alberts, David S ^b   Hixson, Lee J ^b   Paranka, Nancy Shipp ^a   Li, Han ^a   Finn, Tyler ^a   Bogert, Cheryl ^g   Guillen, Jose M ^g   Brendel, Klaus ^b   Gross, Paul H ^d   Sperl, Gerhard ^d   Ritchie, Justine ^c   Burt, Randall W ^e   Ellsworth, Lansing ^b   Ahnen, Dennis J ^f   Pamukcu, Rifat ^a  

^a Cell Pathways Inc   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF THE PACIFIC   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; AZOXYMETHANE; CARCINOGEN; DRUG METABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PIROXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SULINDAC; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER PREVENTION; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME REGULATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; DINOPROSTONE; MALE; RATS; RATS, INBRED F344; SULINDAC;

EID: 0030747817     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Hail, V., DeMello, M., Horakova, Z., and Beaven, M. A. Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J. Pharmacol. Exp. Ther., 202: 446-454, 1977.
2. Hixson, L., Alberts, D., Krutzsch, M., Einspahr, J., Brendel, K., Gross, P. H., Paranka, N. S., Baier, M., Emerson, S., Pamukcu, R., and Burt, R. Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol., Biomarkers & Prev., 3: 433-438, 1994.
3. Bayer, B., Kruth, H., Vaughan, M., and Beaven, M. A. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J. Pharmacol. Exp. Ther., 210: 106-111, 1979.
4. Piazza, G. A., Kulchak-Rahm, A. L., Krutzsch, M., Sperl, G., Shipp-Paranka, N., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukcu, R., and Ahnen, D. J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
5. Shiff, S. J., Qiao, L., and Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits cell proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96: 491-503, 1995.
6. Lu., S., Xie, W., Reed, T., Bradshaw, W. S., and Simmons, D. L. Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 7961-7965, 1995.
7. Elder, D. J. E., Hague, A., Hicks, D. J., and Paraskeva, C. Different growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res., 56: 2273-2276, 1996.
8. Hial, V., Horakova, Z., Shaff, R. E., and Beaven, M. A. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J. Pharmacol., 37: 367-376, 1976.
9. Tanaka, Y., Tanaka, T., and Ishitsuka, H. Anti-tumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res., 49: 5835-5939, 1989.
10. Tanaka, T., Kojima, T., Yoshimi, N., Sugie, S., and Mori, H. Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis (Lond.), 12: 1949-1952, 1991.
11. Pollard, M., and Luckert, P. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res., 49: 6471-6475, 1989.
12. Reddy, B., Maruyama, H., and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340-5346, 1987.
13. Pollard, M., and Luckert, P. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J. Natl. Cancer Inst., 70: 1103-1105, 1983.
14. Reddy, B. S., Tokumo, K., Kulkarni, N., Aligia, C. and Kelloff, G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis (Lond.), 13: 1010-1023, 1992.
15. 2) against indomethacin. J. Cancer Res. Clin. Oncol., 108: 239-242, 1984.
16. Northway, M., Scobey, M., Cassidy, K. T., and Geisinger, K. R. Piroxicam decreases postirradiation colonie neoplasia in the rat. Cancer (Phila.), 66: 2300-2305, 1990.
17. Skinner, S., Penney, A., Penney, G., and O'Brien, P. E. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg., 126: 1094-1096, 1991.
18. Reddy, B. S., Rao, C. V., Riverson, A., and Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond.), 14: 1493-1497, 1993.
19. Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P., Appleton, D. R., and Watson, A. J. A protective effect of sulindac against chemically-induced primary colonie tumors in mice. J. Pathol., 156: 341-347, 1988.
20. Waddell, W., Gasner, G., Cerise, E. J., and Loughry, R. W. Sulindac for polyposis of the colon. Am. J. Surg., 157: 175-179, 1989.
21. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousett, M., and Attali, P. Sulindac causes regression rectal polyps in familial adenomatous polyposis. Gastroenterology. 101: 635-639, 1991.
22. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, J. A. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
23. Rigau, J., Pique, J., Rubio, E., Planas, R., Tarrech, J. M., and Bordas, J. M. Effects of long-term sulindac therapy on colonie polyposis. Ann. Int. Med., 115: 952-954, 1991.
24. Winde, G., Gumbinger, H. G., Osswald, H., Kemper, F., and Bunte, H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int. J. Colorect. Dis., 8: 13-17, 1993.
25. Winde, G., Schmid, K. W., Schlegal, W., Fischer, R., Osswald, H., and Bunte, H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance therapy. Dis. Colon Rectum, 38: 813-830, 1995.
26. Spagnesi, M. T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A., and Biachini, F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology, 106: 362-366, 1994.
27. Nugent, K. P., Farmer, K. C., Spigelman, A. D., Williams, C. B., and Phillips, R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familiar adenomatous polyposis. Br. J. Surg., 80: 1618-1619, 1993.
28. Pasricha, P. J., Bedi, A., O'Connor, K., Rashid, A., Akhtar, A. J., Zahurak, M. L., Piantadosi, S., Hamilton, S. R., and Giardiello, F. M. The effect of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology, 109: 994-998, 1995.
29. Hirota, C., Iida, M., Aoyagi, K., Matsumoto, T., Tada, S., Yao, T., and Fujishima, M. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer (Phila.), 78: 1660-1665, 1996.
30. Kune, G., Kune, S., and Watson, L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from Melbourne Colorectal Cancer Study. Cancer Res., 48: 4399-4404, 1988.
31. Thun, M., Namboodiri, M., and Heath, C. W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
32. Logan, R. F., Little, J., Hawtin, P. G., and Hardcastle, J. D. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening program. Br. Med. J., 307: 285-289, 1993.
33. Schreinemachers, D. M., and Everson, R. B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.
34. Peleg, I. I., Maibach, H. T., Brown, S. H., and Wilcox, C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Int. Med., 154: 394-399, 1994.
35. Suh, O., Mettlin, C., and Petrelli, N. J. Aspirin use, cancer, and polyps of the large bowel. Cancer (Phila.), 72: 1171-1177, 1993.
36. Giovannucci, E., Rimm, E., Stampfer, M. J., Colditz, G. A., Ascherio, A., and Willett, W. C. Aspirin use and the risk of colorectal cancer and adenoma in the male health professionals. Ann. Int. Med., 121: 241-246, 1994.
37. Paganini-Hill, A., Chao, A., Ross, R. K., and Henderson, B. E. Aspirin use and chronic diseases: a cohort study of the elderly. Br. Med. J. 299: 1247-1250, 1989.
38. Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., and Hennekens, C. H. Low-dose aspirin and incidence of colorectal tumors in the randomized trial. J. Natl. Cancer Inst., 85: 1220-1224, 1993.
39. Greenberg, E. R., Baron, J. A., Freeman, D. H., Mandel, J. S., and Haile, R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl. Cancer Inst., 85: 912-916, 1993.
40. Karmali, R. Proslaglandins and cancer. CA-Cancer J. Clin., 33: 322-332, 1983.
41. Zenser, T. V., and Davis, B. B. Arachidonic acid metabolism. In: V. E. Steele, G. D. Stoner, C. W. Boone, and G. J. Kelloff (eds.), Cellular and Molecular Targets for Chemoprevention. Boca Raton: CRC Press, 223-243, 1992.
42. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
43. Earnest, D., Hixson, L., Fennerty, M. B., Emerson, S. S., and Alberts, D. S. Inhibition of prostaglandin synthesis: potential for chemoprevention of human colon cancer. Cancer Bull., 43: 561-568, 1991.
44. Risas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122: 518-523, 1993.
45. Kulkarni, N., Zang, E., Kelloff, G., and Reddy, B. S. Effect of the chemopreventive agents piroxicam and D,L-a-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis (Lond.), 13: 991-1000, 1992.
46. Duggan, D. E., Hooke, K. F., Risley, E. A., Shen, T. Y., and VanArman, C. G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther., 201: 8-13, 1977.
47. Duggan, D. E., Hare, L. E., Ditzler, C. A., Lei, B. W., and Kwan, K. C. The disposition of sulindac. Clin. Pharmacol. Ther., 21: 326-335, 1977.
48. Hucker, H. B., Stauffer, S. C., White, S. D., Rhodes, R. E., Arison, B. H., Umberhauer, E. R., Bower, R. J., and McMahon, F. G. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-melriyl-1 [p-(methylsulfinyl)-benzylidenyl]-indene-3-acetic acid in the rat, dog, rhesus monkey and man. Drug Metab. Dispos., 1: 721-736, 1973.
49. Strong, H. A., Warner, N. J., Renwick, A. G., and George, C. F. Sulindac metabolism: the importance of an intact colon. Clin. Pharmacol. Ther., 38: 387-393, 1985.
50. Shen, T. Y., and Winter, C. A. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv. Drug Res., 12: 89-245, 1977.
51. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R., and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst., 87: 1259-260, 1995.
52. Charalambous, D., and O'Brien, P. E. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J. Gastoenterol. Hepatol., 11: 307-310, 1996.
53. 2) in rectal mucosa in human subjects. Cancer Epidemiol.. Biomarkers & Prev., 4: 239-244, 1995.
54. Boopathy, R., and Balasubramanian, A. S. Purification and characterization of sheep cyclo-oxygenase. Biochem. J., 239: 371-377, 1986.
55. Egan, R. W., and Gale, P. H. Inhibition of mammalian 5-lipoxygenase by aromatic disulfides. J. Biol. Chem., 260: 11554-11559, 1985.
56. Kemal, C., Louis-Flamberg, P., Krupinski-Olsen, R., and Shorter, A. L. Reductive inactivation of soybean lipoxygenase 1 by catechols: a possible mechanism for regulation of lipoxygenase activity. Biochemistry, 26: 7064-7072, 1987.
57. 2 (Naja naja naja). J. Biol. Chem., 252: 2405-2411, 1977.
58. McCullash, P., and Nelder, J. A. Generalized linear models. London: Chapman and Hall, 1989.
59. Suissa, S., and Shuster, J. Exact unconditional sample sizes for the 2 × 2 binomial trial. J. Royal Stat. Soc. Ser. A, 148: 317-327, 1985.
60. Williamson, R. C. N., Bauer, F. L. R., Terpstra, O. T., Ross, J. S., and Malt, R. A. Contrasting effects of subtotal enteric bypass, enterectomy, and colectomy on azoxymethane-induced intestinal carcinogenesis. Cancer Res., 40: 538-543, 1980.
61. Kumar, S. P., Roy, S. J., Tokumo, K., and Reddy, B. S. Effect of different levels of caloric restriction on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res., 50: 5761-5766, 1990.
62. Soll, A. H., Weinstein, W. M., Kurata, J., and McCarthy, D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Int. Med., 114: 308-319, 1991.
63. Cryer, B., and Feldman, M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch. Intern. Med., 152: 1145-1155, 1992.